BMYBristol-Myers SquibbSigning up patients
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 1,000 (planned)
- Started
- Oct 7, 2024
- Main results expected
- Jul 30, 2030
- Fully finished
- Aug 4, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival (OS) in randomized participants with PD-L1 1% to 49%
Measured over: Up to 5 years
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","eligibilityModule","statusModule"]}
Trial ID NCT06561386 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC